Arbutus Appoints Two New Executives
10 juil. 2023 16h01 HE
|
Arbutus Biopharma Corporation
Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus...
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
21 juin 2023 07h30 HE
|
Arbutus Biopharma Corporation
Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
21 juin 2023 02h01 HE
|
Arbutus Biopharma Corporation
Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or...
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
07 juin 2023 02h01 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus to Present at Jefferies Healthcare Conference
31 mai 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus to Present at JMP Securities Life Sciences Conference
09 mai 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
04 mai 2023 07h30 HE
|
Arbutus Biopharma Corporation
Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161 Filed...
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
27 avr. 2023 03h20 HE
|
Arbutus Biopharma Corporation
Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post- AB-729 treatment AB-161 provides robust anti-HBV...
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
25 avr. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
20 avr. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...